The Biden administration unveiled a new plan to vaccinate eligible Americans against monkeypox, prioritizing those who have been exposed to the virus in states with the highest infection rates.
Hundreds of thousands of doses of the Jynneos vaccine from Bavarian Nordic A/S will be made available under the administration’s new plan through a tiered-allocation system, the US Department of Health and Human Services said Tuesday.
Local officials will also be able to request Emergent BioSolutions Inc.’s ACAM2000 vaccine, but it isn’t recommended for use for everyone, such as immunocompromised people, due to “significant side effects.”
